Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Nursing Department, The Third Xiangya Hospital, Central South University, Changsha, China.
PeerJ. 2023 Mar 17;11:e15019. doi: 10.7717/peerj.15019. eCollection 2023.
Studies have shown that the expressions and working mechanisms of Dihydrolipoamide S-acetyltransferase (DLAT) in different cancers vary. It is necessary to analyze the expressions and regulatory roles of DLAT in tumors systematically.
Online public-platform literature on the relationships between DLAT expression levels and tumor prognosis, methylation status, genetic alteration, drug sensitivity, and immune infiltration has been reviewed. The literature includes such documents as The Cancer Genome Atlas (TCGA), Human Protein Atlas (HPA), Tumor Immune Estimation Resource 2.0 (TIMER2.0), Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and Receiver Operating Characteristic plotter (ROC plotter). The molecular mechanisms of DLAT were explored with the Gene Set Enrichment Analysis (GSEA). The relationship between down-regulated DLAT and autophagy in two liver hepatocellular carcinoma (LIHC) cell lines was confirmed with the western blot method, colony formation assay, and transmission electron microscopy. Tissue microarrays were validated through the immunohistochemical staining of DLAT.
DLAT is upregulated in the LIHC, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and stomach adenocarcinoma (STAD) tumors but is down-regulated in the head and neck squamous cell carcinoma (HNSC) and kidney renal clear cell carcinoma (KIRC) tumors in comparison with normal tissues. For LIHC patients treated with 5-Fluorouracil and Lenvatinib, the DLAT levels of those in the drug-resistant group are significantly high. In LIHC cells, autophagy will be inhibited, and cell death will be induced when DLAT breaks down. Moreover, there exist positive correlations between DLAT expression levels and infiltration of B cells, DC cells, Tregs, and CD8+ T cells in kidney chromophobe (KICH), breast invasive carcinoma (BRCA), prostate adenocarcinoma (PRAD), LIHC and HPV+ HNSC. In LIHC, markers of Tregs are positively correlated with DLAT. Compared with those of normal tissues, the staining intensity of DLAT and the amount of Tregs marker CD49d in LIHC increase.
Through this study, the expressions of DLAT in various cancer types can be understood comprehensively. It suggests that DLAT may be a prognostic marker for LIHC, LUAD, LUSC, STAD and KIRC. A high DLAT expression in LIHC may promote tumorigenesis by stimulating autophagy and inhibiting anti-tumor immunity.
研究表明,二氢硫辛酰胺 S-乙酰基转移酶(DLAT)在不同癌症中的表达和作用机制不同。有必要系统地分析 DLAT 在肿瘤中的表达和调控作用。
在线查阅了与 DLAT 表达水平与肿瘤预后、甲基化状态、遗传改变、药物敏感性和免疫浸润关系相关的公共文献平台的文献。文献包括癌症基因组图谱(TCGA)、人类蛋白质图谱(HPA)、肿瘤免疫估计资源 2.0(TIMER2.0)、基因表达谱交互式分析 2(GEPIA2)和接收者操作特征图(ROC plotter)等。通过基因集富集分析(GSEA)探索了 DLAT 的分子机制。通过蛋白质印迹法、集落形成实验和透射电镜证实了下调的 DLAT 与两种肝癌细胞系(LIHC)中的自噬之间的关系。通过免疫组织化学染色 DLAT 对组织微阵列进行了验证。
与正常组织相比,DLAT 在 LIHC、肺腺癌(LUAD)、肺鳞状细胞癌(LUSC)和胃腺癌(STAD)肿瘤中上调,但在头颈部鳞状细胞癌(HNSC)和肾透明细胞癌(KIRC)肿瘤中下调。对于接受 5-氟尿嘧啶和仑伐替尼治疗的 LIHC 患者,药物耐药组的 DLAT 水平显著升高。在 LIHC 细胞中,当 DLAT 分解时,自噬会受到抑制,细胞死亡会被诱导。此外,在肾嫌色细胞癌(KICH)、乳腺癌浸润性癌(BRCA)、前列腺腺癌(PRAD)、LIHC 和 HPV+头颈部鳞状细胞癌(HNSC)中,DLAT 表达水平与 B 细胞、DC 细胞、Tregs 和 CD8+T 细胞的浸润之间存在正相关。在 LIHC 中,Tregs 标志物与 DLAT 呈正相关。与正常组织相比,LIHC 中 DLAT 的染色强度和 Tregs 标志物 CD49d 的数量增加。
通过这项研究,可以全面了解各种癌症类型中 DLAT 的表达情况。这表明 DLAT 可能是 LIHC、LUAD、LUSC、STAD 和 KIRC 的预后标志物。LIHC 中高表达的 DLAT 可能通过刺激自噬和抑制抗肿瘤免疫来促进肿瘤发生。